Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate

Simply Wall St · 10/26 02:00

Key Insights

  • Gland Pharma's estimated fair value is ₹1,304 based on 2 Stage Free Cash Flow to Equity
  • Current share price of ₹1,606 suggests Gland Pharma is potentially 23% overvalued
  • The ₹1,920 analyst price target for GLAND is 47% more than our estimate of fair value

Today we will run through one way of estimating the intrinsic value of Gland Pharma Limited (NSE:GLAND) by taking the expected future cash flows and discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

View our latest analysis for Gland Pharma

Is Gland Pharma Fairly Valued?

We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) estimate

2025 2026 2027 2028 2029 2030 2031 2032 2033 2034
Levered FCF (₹, Millions) ₹1.86b ₹8.14b ₹10.5b ₹12.5b ₹14.4b ₹16.2b ₹18.0b ₹19.7b ₹21.4b ₹23.1b
Growth Rate Estimate Source Analyst x6 Analyst x6 Analyst x6 Est @ 18.64% Est @ 15.06% Est @ 12.55% Est @ 10.80% Est @ 9.57% Est @ 8.71% Est @ 8.10%
Present Value (₹, Millions) Discounted @ 12% ₹1.7k ₹6.5k ₹7.5k ₹7.9k ₹8.1k ₹8.1k ₹8.1k ₹7.9k ₹7.6k ₹7.4k

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = ₹71b

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 6.7%. We discount the terminal cash flows to today's value at a cost of equity of 12%.

Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = ₹23b× (1 + 6.7%) ÷ (12%– 6.7%) = ₹453b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= ₹453b÷ ( 1 + 12%)10= ₹144b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is ₹215b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of ₹1.6k, the company appears slightly overvalued at the time of writing. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

dcf
NSEI:GLAND Discounted Cash Flow October 26th 2024

Important Assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Gland Pharma as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 12%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

SWOT Analysis for Gland Pharma

Strength
  • Debt is not viewed as a risk.
  • Dividends are covered by earnings and cash flows.
  • Dividend is in the top 25% of dividend payers in the market.
Weakness
  • Earnings declined over the past year.
Opportunity
  • Annual earnings are forecast to grow faster than the Indian market.
  • Good value based on P/E ratio compared to estimated Fair P/E ratio.
Threat
  • Revenue is forecast to grow slower than 20% per year.

Looking Ahead:

Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Can we work out why the company is trading at a premium to intrinsic value? For Gland Pharma, we've put together three relevant items you should assess:

  1. Risks: For example, we've discovered 2 warning signs for Gland Pharma that you should be aware of before investing here.
  2. Future Earnings: How does GLAND's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. Simply Wall St updates its DCF calculation for every Indian stock every day, so if you want to find the intrinsic value of any other stock just search here.